Northwest Biotherapeutics Inc (NWBO) Stock Price & News

Markets

Europe

Asia

Currencies

Crypto

Futures

Goldman Sachs, Microsoft Power Dow Industrials to 40000• WSJ• 1 day ago

Dow Jones40,003.59+0.34%+134.21Dow Jones40,003.590.34%

Nasdaq16,685.97-0.074%-12.35Nasdaq16,685.970.074%

Russell2,095.72-0.025%-0.53Russell2,095.720.025%

VIX11.99-3.46%-0.43VIX11.993.46%

HomeNWBO • OTCMKTS

Northwest Biotherapeutics Inc

$0.47

May 17, 8:10:00 PM GMT-4 · USD · OTCMKTS · Disclaimer

Key events shows relevant news articles on days with large price movements

CytoDyn Inc

$0.20

CYDY11.79%

Vivos Inc

$0.18

RDGL3.04%

Anavex Life Sciences Corp

$4.55

AVXL1.11%

Netlist Inc

$1.64

NLST15.49%

Enzolytics Inc

$0.0038

ENZC1.79%

Northwest Bancshares Inc

$11.40

NWBI0.62%

Federal National Mortgage Association

$1.60

FNMA1.59%

InnerScope Hearing Technologies, Inc.

$0.00020

INND20.00%

Citius Pharmaceuticals Inc

$0.65

CTXR2.86%

Jaguar Health Inc

$0.26

JAGX9.84%

Market news

Investor's Business Daily

1 hour ago

Futures: Nvidia Offers Huge Test; 5 AI Stocks Near Buy Points

.DJI0.34%

Dow Jones Industrial Average

NVDA1.99%

NVIDIA Corp

Tipranks

10 hours ago

Bank of America Predicts up to ~200% Surge for These 2 'Strong Buy' Stocks - TipRanks.com

BAC0.18%

Bank of America Corp

.INX0.12%

S&P 500

The Motley Fool

11 hours ago

Want to Beat the S&P 500? History Says Avoid This Top Warren Buffett Stock

BRK.A0.68%

Berkshire Hathaway Inc Class A

.INX0.12%

S&P 500

MSNBC News

1 day ago

A Dow record high doesn't fix Biden's biggest problem. Here's what will.

CNN

2 days ago

Dow closes above 40,000 for first time ever

.DJI0.34%

Dow Jones Industrial Average

CNBC

2 days ago

Here's what has driven the Dow rally to 40,000, and why it could keep going

.DJI0.34%

Dow Jones Industrial Average

Financials

Income Statement



Revenue

Net income

(USD)	Mar 2024info Fiscal Q1 2024 ended 3/31/24.	Y/Y change
Revenue The total amount of income generated by the sale of goods or services related to the company's primary operations	284.00K	-67.73%
Operating expense Represents the total incurred expenses through normal operations	8.09M	15.80%
Net income Company’s earnings for a period net of operating costs, taxes, and interest	-18.31M	-71.91%
Net profit margin Measures how much net income or profit is generated as a percentage of revenue.	-6.45K	-432.69%
Earnings per share Represents the company's profit divided by the outstanding shares of its common stock.	—	—
EBITDA Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circ*mstances	-15.32M	-21.28%
Effective tax rate The percent of their income that a corporation pays in taxes	—	—

Balance Sheet



Total assets

Total liabilities

(USD)	Mar 2024info Fiscal Q1 2024 ended 3/31/24.	Y/Y change
Cash and short-term investments Investments that are relatively liquid and have maturities between 3 months and one year	2.48M	-59.97%
Total assets The total amount of assets owned by a company	28.57M	-13.09%
Total liabilities Sum of the combined debts a company owes	82.04M	26.03%
Total equity The value of subtracting the total liabilities from the total assets of a company	-53.47M	—
Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing	1.21B	—
Price to book A ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock	-8.00	—
Return on assets A financial ratio that shows a company’s profitability compared to its assets	-139.50%	—
Return on capital Company’s return above the average cost it pays for its debt and equity capital	1,336.50%	—

Cash Flow



Net change in cash

(USD)	Mar 2024info Fiscal Q1 2024 ended 3/31/24.	Y/Y change
Net income Company’s earnings for a period net of operating costs, taxes, and interest	-18.31M	-71.91%
Cash from operations Net cash used or generated for core business activities	-12.41M	-10.38%
Cash from investing Net cash used or generated in investing activities such as purchasing assets	-239.00K	82.07%
Cash from financing Net cash used or generated in financing activities such as dividend payments and loans	12.08M	-3.95%
Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period	352.00K	145.48%
Free cash flow Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments	-5.70M	93.32%

Stock

Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned

US listed security

Listed on OTCMKTS

Previous close

The last closing price

$0.48

Day range

The range between the high and low prices over the past day

$0.47 - $0.49

Year range

The range between the high and low prices over the past 52 weeks

$0.40 - $1.09

Market cap

A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.

562.41M USD

Avg Volume

The average number of shares traded each day over the past 30 days

1.46M

P/E ratio

The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks

Dividend yield

The ratio of annual dividend to current share price that estimates the dividend return of a stock

Primary exchange

Listed exchange for this security

OTCMKTS

About



Northwest Biotherapeutics is a development-stage American pharmaceutical company headquartered in Maryland that focuses on developing immunotherapies against different types of cancer. It was founded in 1996 by Alton L. Boynton. Wikipedia

Founded

Jan 1, 1998

Website

nwbio.com

Employees

Discover more

FAQs

Is NWBO a good investment? ›

OTC Stocks USA . Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Northwest Biotherapeutics is 'Strong Sell'.

Tell Me More ›

What is the stock price forecast for NWBO in 2024? ›

Northwest Biotherapeutics Inc quote is equal to 0.432 USD at 2024-06-15. Based on our forecasts, a long-term increase is expected, the "NWBO" stock price prognosis for 2029-06-06 is 0.697 USD. With a 5-year investment, the revenue is expected to be around +61.45%.

See Details ›

What is the price target for NWBO? ›

Stock Price Targets

High	$15.10
Median	$15.10
Low	$15.10
Average	$15.10
Current Price	$0.4450

Learn More Now ›

What is the potential of NWBO? ›

NWBO Broker Recommendations Summary

NWBO has a greater upside potential (average analyst target price relative to current price) than 98.79% of all US stocks. The average analyst price target of NWBO is higher than 29.11% of all US stocks.

Get More Info Here ›

What is the forecast for Northwest Healthcare REIT? ›

Based on 6 Wall Street analysts offering 12 month price targets for NorthWest Healthcare Properties REIT in the last 3 months. The average price target is C$5.75 with a high forecast of C$6.50 and a low forecast of C$5.25. The average price target represents a 13.37% change from the last price of C$5.07.

What is the target price for next stock? ›

NEXT Stock 12 Month Forecast

Based on 2 Wall Street analysts offering 12 month price targets for NextDecade in the last 3 months. The average price target is $9.00 with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 15.09% change from the last price of $7.82.

Know More ›

Is NWBO an OTC stock? ›

NWBO Stock Price | Northwest Biotherapeutics Inc. Stock Quote (U.S.: OTC) | MarketWatch.

Show Me More ›

What is DCVax l? ›

It is a type of immunotherapy known as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, DCVax-L is a personalised vaccine made from each patient's own dendritic cells – a type of cell that helps the immune system recognise and attack cancer cells.

Get More Info ›

What is the future of Annaly Capital? ›

NLY Stock 12 Month Forecast

Based on 5 Wall Street analysts offering 12 month price targets for Annaly Capital in the last 3 months. The average price target is $20.95 with a high forecast of $22.00 and a low forecast of $19.25. The average price target represents a 5.38% change from the last price of $19.88.

Know More ›

What is the price prediction for Newmont? ›

The average price target for Newmont Mining is $48.40. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $54.00 ,the lowest forecast is $45.00. The average price target represents 18.08% Increase from the current price of $40.99.

Discover More ›

Will PSEC go up? ›

PSEC Stock 12 Month Forecast

Based on 1 Wall Street analysts offering 12 month price targets for Prospect Capital in the last 3 months. The average price target is $5.00 with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a -9.75% change from the last price of $5.54.

Northwest Biotherapeutics Inc (NWBO) Stock Price & News - Google Finance (2024)

FAQs

Is NWBO a good investment? ›

What is the target price for next stock? ›